December 2nd 2024
If granted, guselkumab will be approved to treat children ages 6 and younger with severe plaque psoriasis and children ages 5 and younger with juvenile psoriatic arthritis.
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis
View More
Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?
View More
Tattoos temporary, reactions persist
August 1st 2005New Orleans — The increased popularity of temporary, dark henna body tattoos appears to be providing dermatologists with more cases of allergic contact dermatitis as well as a new area in which to counsel patients about safety. According to Mukta Sachdev, M.D., F.A.A.D., adverse reactions to certain types of temporary henna tattoos are on the increase, and dermatologists have the opportunity to educate and advise patients about potential risks associated with this form of body art.
New advances offer insight about immune system
July 1st 2005Buenos Aires, Argentina — Recent advances in the understanding of the skin immune system are represented in four major areas of research: Langerhans cell trafficking, innate immunity, complex genetic diseases with an immunologic basis and psoriasis, according to Stephen I. Katz, M.D., Ph.D., director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Md. Dr. Katz says, in each of these areas, there are potential therapeutic interventions.
Pediatric melanoma on rise, some say
July 1st 2005Charles M. Balch, M.D., used to see a pediatric melanoma case every one to two years. In recent years, the professor of surgery and oncology at Johns Hopkins Medical Institution, Baltimore, Md., says he sees a child or teenager with melanoma every one to two months.
Breaking the myth: Bronze isn't beautiful
July 1st 2005Schaumburg, Ill. — Many men, women and teenagers still believe that a tan looks healthy, according to several American Academy of Dermatology (AAD) surveys that polled Americans to determine their opinions of tanning and health. The polls also found that regardless of health risk, many people don't guard against sun exposure.
Trial reveals benefits of excimer laser on early-stage mycosis fungoides
June 1st 2005New Orleans — Mycosis fungoides (MF), the most common form of cutaneous T-cell lymphoma, has been most commonly treated in its early stages with skin-directed therapies such as topical corticosteroids, nitrogen mustard, UVB, PUVA and total skin electron beam irradiation. More recently, dermatologists have begun using narrow-band UVB with a spectrum peak of 311 nm as an alternative treatment for early-stage MF.
Ciclopirox shampoo eases seborrheic dermatitis
June 1st 2005Antipityrosporal 1 percent ciclopirox shampoo can be used weekly or once every two weeks to treat seborrheic dermatitis and prophylactically to prevent its recurrence, according to a study published in the Archives of Dermatology in January.